References
- 1. Aleksandric S, Tomasevic M, Dobric M, Beleslin B, Tasic M. Antitrombocitna terapija u sekundarnoj prevenciji. Srce i krvni sudovi 2011;30(4):224-233.
- 2. Gurbel PA, Myat A, Kubica J, Tantry US. State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis 2016;5:1-10.
- 3. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16):1706-1717.
- 4. ISIS-2 trial. Second International Study of Infarct Survival) collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both, or either among 17 187 cases of suspected acute myocardial infarction: Lancet 1988;2(8607):349-360.
- 5. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
- 6. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
- 7. Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001;119(1 Suppl):321S-36S.
- 8. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a metaanalysis. Am J Med 2008;121(1):43–49.
- 9. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) collaborative group. Lancet 1997; 349(9066):1641-1649.
- 10. Miedema MD, Huguelet J, Virani SS. Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity. Curr Atheroscler Rep 2016;18(1):4. doi: 10.1007/s11883-015-0555-0. Review.
- 11. ASCEND trial. A Study of Cardiovascular Events in Diabetes. Available from: http://www.ctsu.ox.ac.uk/ascend.
- 12. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.
- 13. Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008;189:105-109.
- 14. Bayer ARRIVE aspirin research study. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Trial. Available from: http://www.arrive-study.com/EN/study.cfm
- 15. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention. A position paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 2014;64:319–327.10.1016/j.jacc.2014.03.049
- 16. Cheng JW. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2013;18(6):514-524.
- 17. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678): 1849-1860.
- 18. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e637S–668S.
- 19. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. J Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-313.
- 20. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150(6):396-404.
- 21. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164(12):826-835.
- 22. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312:2510-2220. [PMID: 25401325] doi:10.1001/jama.2014.15690.
- 23. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22. [PMID: 16987411].
- 24. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-391.
- 25. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011;123:1243-1262.
- 26. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315-2381.
- 27. Lanas A, Polo-Tomas M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator - a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37: 738-748. [PMID: 23413984] doi:10.1111/apt.12240.
- 28. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10:e0124653. [PMID:26061035] doi:10.1371/journal.pone.0124653.
- 29. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55-63. [PMID: 25560714] doi:10.7326/M14-0697.
- 30. Belch J, MacCuish A, Campbell I, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
- 31. Ogawa H, NakayamaM, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134–2141.
- 32. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303(9):841–848.
- 33. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312(23):2510–2520.
- 34. Bartolucci AA, Tendera M, Howard G. Metaanalysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796–1801.
- 35. Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621–629.
- 36. Berger JS, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a metaanalysis of randomized trials. Am Heart J 2011;162:115–124, e2.
- 37. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta- analysis of randomized controlled trials. Arch Intern Med 2012;172:209–16.
- 38. De Berardis G, Sacco M, Strippoli GF, Pellegret al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. doi: 10.1136/bmj.b4531.10.1136/bmj.b4531
- 39. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. Circulation. 2010;121:2694-2701.